

115TH CONGRESS
2D SESSION

H. R. 5712

To amend title XIX of the Social Security Act to compel manufacturers to correct inaccurate classification data reported to the Medicaid rebate program, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MAY 8, 2018

Mr. SCHRADER (for himself and Mr. WELCH) introduced the following bill;
which was referred to the Committee on Energy and Commerce

A BILL

To amend title XIX of the Social Security Act to compel manufacturers to correct inaccurate classification data reported to the Medicaid rebate program, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Medicaid Drug Rebate
5 Accountability Act”.

1 **SEC. 2. AUTHORITY TO COMPEL MANUFACTURERS TO COR-**
2 **RECT INACCURATE CLASSIFICATION DATA**
3 **REPORTED TO MEDICAID REBATE PROGRAM.**

4 Section 1927(b)(3) of the Social Security Act (42
5 U.S.C. 1396r-8(b)(3)) is amended by adding at the end
6 the following new subparagraph:

7 “(E) REMEDY WITH RESPECT TO INAC-
8 CURATE CLASSIFICATION DATA.—

9 “(i) CORRECTION OF INACCURATE
10 CLASSIFICATION DATA.—In the case that
11 the Secretary determines that drug classi-
12 fication data reported on or after Sep-
13 tember 30, 2018, by a manufacturer under
14 this paragraph, with respect to a covered
15 outpatient drug of such manufacturer, pro-
16 vides an inaccurate classification for such
17 drug, the Secretary shall require such
18 manufacturer to correct, within a 30-day
19 period, the classification for such drug.

20 “(ii) CIVIL MONETARY PENALTY.—In
21 the case of a manufacturer who fails to
22 correct the classification of a covered out-
23 patient drug within a 30-day period pursu-
24 ant to clause (i), the Secretary shall, be-
25 ginning the day after the end of such 30-
26 day period, require such manufacturer to

1 pay a civil monetary penalty of \$100,000
2 per day until the date on which the manu-
3 facturer corrects such classification.

4 “(iii) CLASSIFICATION DEFINED.—
5 For purposes of this subparagraph, the
6 term ‘classification’ means identification or
7 designation as one of the following:

8 “(I) A single source drug.

9 “(II) An innovator multiple
10 source drug.

11 “(III) A noninnovator multiple
12 source drug.”.

○